AI주식인사이트AI Stock Insight
C

랩지노믹스

084650KOSDAQ자연과학 및 공학 연구개발업

43.0 / 100

Reference Date: 2026-04-13

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Declined 11.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Labgenomics specializes in genetic molecular diagnostics, including non-invasive prenatal testing (NIPT), cancer gene screening, and chromosomal abnormality detection. As the first company in South Korea to commercialize NIPT, it leads the market with its 'MomGuard' product line and continues to expand its portfolio with innovations like the LabGun COVID-19 assay and early Alzheimer's diagnostic kits.

Number of Employees

142people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
0.63Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE
-35.18Industry Average -32.113.5Point

In line with industry avg

Debt Ratio
13.61Industry Average 7.520.5Point

1.8x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼180.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -16.1% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 1Neutral 2Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 1,268Won52-week high 3,12052-week low 1,218
1-month return1.0Point

1m -11.33% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0
  • Neutral기타경영사항(자율공시) (업무제휴계약 체결)2026-04-01
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral정기주주총회결과2026-03-31
  • Neutral감사보고서제출2026-03-23
  • Neutral사업보고서 (2025.12)2026-03-23